Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 133Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Myelodysplastic Syndromes 111Leukemia, Lymphocytic, Chronic, B-Cell 101Lymphoma, Non-Hodgkin 97Hodgkin Disease 94Leukemia 85Multiple Myeloma 84Lymphoma 71Lymphoma, Mantle-Cell 66Lymphoma, Follicular 66Lymphoma, Large B-Cell, Diffuse 63Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Myeloproliferative Disorders 58Lymphoma, B-Cell, Marginal Zone 57Burkitt Lymphoma 52Leukemia, Myelomonocytic, Chronic 51Congenital Abnormalities 50Leukemia, Myeloid, Chronic-Phase 49Lymphoma, Large-Cell, Immunoblastic 45Leukemia, Myeloid, Accelerated Phase 42Hematologic Neoplasms 42Anemia, Refractory, with Excess of Blasts 40Graft vs Host Disease 39Primary Myelofibrosis 36Waldenstrom Macroglobulinemia 33Neoplasms, Plasma Cell 32Blast Crisis 32Lymphoma, T-Cell, Cutaneous 30Recurrence 29

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans Syndrome × Mycophenolic Acid × Clear all
NCT04959175 2026-04-28

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
320 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05327023 2026-04-28

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
430 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡